Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1992-7-2
|
pubmed:abstractText |
The effect of reducing the dose of peroral lynestrenol by half on serum sex-hormone, lipid and lipoprotein status was studied in 21 mentally retarded women with therapeutic amenorrhea (TA). They had previously received 5 or 10 mg peroral lynestrenol daily for periods ranging from 32 to 196 months. Dose halving of lynestrenol resulted in an increase in serum total testosterone (T) by 16% (p less than 0.05), sex-hormone binding globulin (SHBG) by 39% (p less than 0.01) and high-density lipoprotein cholesterol (HDL-C) by 28% (p less than 0.001). Both the mean serum total and free concentrations of norethisterone (NET and fNET) decreased by 60% (p less than 0.001). The serum concentrations of 17-beta-estradiol (E2), its free fractions (fE2) and free T (fT) were not significantly altered. Significant correlations were observed between the change in HDL-C and the change in T (r = 0.45, p less than 0.05), between the change in SHBG and the change in T (r = 0.62, p less than 0.01), fT (r = 0.43, p less than 0.05) and E2 (r = 0.51, p less than 0.05). The elevation of HDL-C was probably caused by the reduced serum NET concentrations. This also resulted in an increase in serum SHBG concentration, which is regarded as an indicator of the overall estrogen/androgen ratio.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Gonadal Steroid Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Lynestrenol,
http://linkedlifedata.com/resource/pubmed/chemical/Norethindrone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0001-6349
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
71
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
175-80
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1317638-Adult,
pubmed-meshheading:1317638-Amenorrhea,
pubmed-meshheading:1317638-Cholesterol,
pubmed-meshheading:1317638-Dose-Response Relationship, Drug,
pubmed-meshheading:1317638-Female,
pubmed-meshheading:1317638-Gonadal Steroid Hormones,
pubmed-meshheading:1317638-Humans,
pubmed-meshheading:1317638-Intellectual Disability,
pubmed-meshheading:1317638-Lipids,
pubmed-meshheading:1317638-Lipoproteins,
pubmed-meshheading:1317638-Lynestrenol,
pubmed-meshheading:1317638-Norethindrone,
pubmed-meshheading:1317638-Radioimmunoassay
|
pubmed:year |
1992
|
pubmed:articleTitle |
Lynestrenol induced therapeutic amenorrhea: effects of dose reduction on serum sex-hormones and lipids.
|
pubmed:affiliation |
Rinnekoti Institute for the Mentally Retarded, University of Helsinki, Finland.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|